Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
Executive Summary
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
You may also be interested in...
Reckitt Grows Its Personal-Care Clout, Asia Footprint With $724M Paras Buy
Reckitt Benckiser will enhance its personal-care offering and position itself for growth in the dynamic Indian market with its acquisition of Paras Pharmaceuticals Ltd. for roughly $725 million.
Merck KGaA And Sanofi-Aventis To Co-Develop Cancer Drugs
In a rare early-stage R&D collaboration, two Big Pharmas will evaluate novel combinations of signaling-pathway anticancers.
FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases
FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.